Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methanesulfonamide SCHEMBL9236534 | 0.96 | — | — | |
| Pyrrolidine SCHEMBL28068383 | 0.87 | CA1 (0.50) | CA1CXCR4SMN1; SMN2KDM4EAPLNR | |
| Methanesulfonamide SCHEMBL5518031 | 0.86 | — | — | |
| Piperazine SCHEMBL10271925 | 0.85 | CA1 (0.50) | CA1HIF1AMAPTPDE4AKDR | |
| Sulfamide SCHEMBL4141697 | 0.81 | — | — | |
| Piperazine SCHEMBL28064448 | 0.80 | CA2 (0.38) | CA1HIF1AMAPTPDE4AKDR | |
| Piperazine SCHEMBL18544339 | 0.79 | CA5A (0.57) | CA1HIF1AMAPTPDE4AKDR | |
| Piperazine SCHEMBL27613760 | 0.79 | CXCR4 (0.44) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL11121855 | 0.79 | CYP3A4 (0.46) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL2585493 | 0.79 | CYP3A4 (0.46) | HIF1AMAPTPDE4AKDRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1159292-A2 | COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | Administrators of The Tulane Educational Fund (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000009537-A2 | COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2000-02-24 | — | — | WO | claimed |
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2005-11-10 | — | — | US | disclosed |
| US-6878700-B1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-04-12 | — | — | US | disclosed |
| US-6867203-B2 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1481968-A2 | Cell adhesion-inhibiting anti-inflammatory and immune-suppressive compounds | Abbott Laboratories (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1165505-B1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LAB (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040116518-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
| CN-1353691-A | Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds | ABBOTT LAB (US) | 2002-06-12 | — | — | CN | disclosed |
| EP-1165505-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059880-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-10-12 | — | — | WO | disclosed |
| US-5777112-A | PIPERAZINE AMIDES FOR FEEDS | MERCK & CO., INC (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1995034311-A1 | PIPERAZINE COMPOUNDS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ICAM1, VCAM1, EPCAM | CA1 3351/4885HIF1A 951/4885MAPT 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.